ORIGINAL RESEARCH article

Front. Immunol.

Sec. Cancer Immunity and Immunotherapy

Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1607098

This article is part of the Research TopicImmune Predictive and Prognostic Biomarkers in Immuno-Oncology: Refining the Immunological Landscape of CancerView all 32 articles

Exploring of bladder cancer immune-related genes and potential therapeutic targets based on transcriptomic data and Mendelian randomisation analysis

Provisionally accepted
Zhangxiao  XuZhangxiao Xu1,2Juan  YangJuan Yang1,2Yira  MaYira Ma1,2Bo  TaoBo Tao1Yunpeng  HeYunpeng He1Jian  WuJian Wu1Yuan  ZhaoYuan Zhao1Yuanjian  NiuYuanjian Niu1Lijun  WangLijun Wang1*
  • 1Department of Urinary Surgery, Anning First People's Hospital Affiliated to Kunming University of Science and Technology, Kunming, Yunnan Province, China
  • 2Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming, Yunnan Province, China

The final, formatted version of the article will be published soon.

Background: Despite advancements in clinical treatment modalities, immune-related molecular mechanisms underlying bladder cancer remain unclear. Therefore, this study aimed to identify immune-related biomarkers and potential therapeutic targets for bladder cancer, thereby contributing to the development of novel therapeutic interventions.By integrating data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and genome-wide association study (GWAS) databases, combined with differential expression analysis, weighted gene co-expression network analysis (WGCNA), and Mendelian randomization analysis, key immune-related genes in bladder cancer were identified. The correlation between these key genes and immune cell infiltration was also analyzed. The diagnostic efficacy of the key genes was evaluated using Receiver Operating Characteristic (ROC) curves and validated using independent public datasets. Finally, Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to confirm the potential value of these molecular markers in bladder cancer.Results: Differential expression analysis revealed 2,033 bladder cancer-related genes. WGCNA identified 1,391 immune-related genes and Mendelian randomization analysis identified 187 candidate genes with causal relationships. Eight significantly downregulated genes were identified: LIMS2, TP53INP2, IRAK3, STX2, CYP27A1, IL11RA, KCNMB1, and PDLM7. These genes were significantly associated with immune cell infiltration and exhibited good diagnostic efficacy, as demonstrated by ROC curve analysis and validated in independent public datasets. Furthermore, qRT-PCR experiments showed that LIMS2, IRAK3, STX2, IL11RA, KCNMB1, and PDLM7 were significantly downregulated in the tumor group, consistent with the bioinformatic analysis results, suggesting their potential clinical value.This study identified six immunoregulatory genes that were significantly negatively associated with bladder cancer risk. These genes may serve not only as potential biomarkers for bladder cancer immunity but also contribute to a deeper understanding of the molecular mechanisms of bladder cancer.

Keywords: Bladder cancer, Mendelian Randomization Analysis, WGCNA, CIBERSORT, biomarkers, potential therapeutic targets

Received: 07 Apr 2025; Accepted: 04 Jul 2025.

Copyright: © 2025 Xu, Yang, Ma, Tao, He, Wu, Zhao, Niu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Lijun Wang, Department of Urinary Surgery, Anning First People's Hospital Affiliated to Kunming University of Science and Technology, Kunming, Yunnan Province, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.